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Abstract 
Breast cancer is a first magnitude problem of public health worldwide. There is 
increasing evidence that this cancer is originated in and maintained by a small population 
of undifferentiated cells with self-renewal properties. This small population generates a 
more differentiated pool of cells which represents the main mass of the tumor, resembling 
the hierarchical tissue organization of the normal breast. These cancer stem cells seem to 
share a similar phenotype with their normal counterparts but they display dysfunctional 
patterns of proliferation and differentiation, and they no longer respond to normal 
physiological controls that ensure a balanced cellular turnover. The origin of these cancer 
stem cells is controversial; it is not well known if they are originated from normal stem 
cells or from more differentiated progenitors where a de novo stem cell program is 
activated by the oncogenic insult.  Here we review the origin of breast cancer stem cells 
and their role in the pathogenesis of cancer development, together with their implications 
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INTRODUCTION 
The hierarchical tissue organization of cellular replacement by stem cells was originally 
described in 1965 by Gilbert and Lajtha in the hematopoietic system [1]; this concept has 
been later extrapolated to other tissues including breast [2-4]. In the last few years, the 
characterization of stem cells in different organs supports the hypothesis that all tissues 
have stem cells and, to some degree, a hierarchical organization [5]. The term stem cell 
defines cells with self-renewal potency and the ability to give rise to multiple lineages; in 
normal adult tissues stem cells are responsible for generating and maintaining the tissue 
architecture and for ensuring a balanced cellular turnover. The equilibrium between cell 
renewal and cell loss is carefully controlled by communications between tissue stem cells 
and the microenvironment to permit precise responses to stresses caused by tissue 
damage or to control normal tissue remodeling [6]. Mammary gland is a very dynamic 
organ, with big fluctuations in cell proliferation in every menstrual cycle and also 
undergoes enormous developmental changes during pregnancy, lactation and involution. 
These processes are properly controlled by systemic hormones and by local epithelial-
stromal interactions [7], and suggest the existence of stem cells able to generate new 
lobules during mammary remodeling. In 1959, DeOme and collaborators observed that 
the parenchyma isolated from different regions of the breast was able to generate 
mammary tissue outgrowths containing different cell lineages of the mammary gland and 
proposed the existence of mammary stem cells [8]. Earlier studies by Pierce and 
collaborators suggested that not only normal cell lineages of the mammary gland, but also 
breast cancer would have the origin in and be maintained by stem cells (cancer stem 
cells) [9-11]. It seems clear that breast cancer is developed after decades of the oncogenic 
initiation [12, 13] and, due to the high cellular turnover of the mammary gland, stem cells 
would be the only subpopulation present in the tissue enough time which provide to 
accumulate all the oncogenic alterations needed to generate cancer [14-19]. There is a 
question of controversy if these cancer stem cells would have the origin in their normal 
counterparts or the oncogenic insult would induce a stem cell-like program in a more 
differentiated progenitor [6]. 
In this article we summarize the current information about normal mammary stem 
cells, breast cancer hierarchy, and mammary cancer stem cells. We also discuss the 
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implications of cancer stem cell hypothesis in cancer initiation and tumor cell fate, and its 
clinical consequences in dissemination, relapse, treatment and susceptibility. Lastly, we 
shortly summarize the molecular pathways related with stem cell self-renewal capacity. 
 
 NORMAL BREAST STEM CELLS       
The epithelial component of the mammary tissue is composed by different cell lineages 
including ductal, alveolar and myoepithelial cells. In parallel with other organs, mainly 
the hematopoietic tissue, it was suggested that all these glandular cells could have their 
origin in the same cell progenitor with self-renewal capability, indicating there would be 
a hierarchical tissue organization in the mammary gland (Fig. 1). This idea was supported 
by several pieces of evidence. Firstly, the physiological characteristics of the mammary 
gland itself, with high remodeling capacity necessary for its continuous cycles of 
involution and redevelopment, indicate the requirement of stem cells to permit this high 
cellular turnover. Secondly, there is the fact that entire lobules of the gland sometimes 
contain identical X-chromosome inactivation in all cells, independently of the cell 
lineage, indicating their clonal origin [20]. This is similar to what is demonstrated in 
mammary tumors which can also be composed from different cell types, but all of them 
share similar chromosomal aberrations indicating a clonal origin too [21, 22]. Lastly, 
small portion of the developing tissue or even the lactating organ can generate a complete 
mammary gland with the entire branching tree. All these data together, suggest the clonal 
origin of the epithelial cells of the mammary gland and the existence of stem cells. This 
idea was strongly supported by the elegant work done by Kordon and Smith who 
demonstrated that a single retrovirally marked epithelial cell can reconstitute the whole 
mammary gland [2], and this was further later confirmed later on by two recent works 
demonstrating that the entire mammary gland can be regenerated by the progeny of a 
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Identification of Mammary Stem Cells 
The data suggesting the existence of mammary stem cells lead to develop a number of 
approaches to isolate and identify these cells. An interesting strategy to recognize 
mammary stem cells is based on the defined characteristic that stem cells are mostly 
quiescent and infrequently divides, for this reason retain labeled DNA precursors like 
bromodeoxyuridine [23-25]; thus stem cells are included in the pool known as Label 
Retaining Cells (LRCs). This strategy has permitted the use of these population rich in 
putative stem cells to analyze markers that define the stem cell compartment. In this 
regard, it has been demonstrated that LRCs express P21 and Mushashi-1 which have been 
previously considered as stem cell markers [26]. A similar strategy with H3-thymidine 
permitted Pierce and collaborators in the 70’s, demonstrated the existence of LRCs in 
tumors and proposed the existence of putative breast cancer stem cells [10, 11].   
Other strategy to identify stem cells is based on their ability to exclude dyes such 
as Hoechst, feature owed to the expression of a family of membrane transporters [27, 28]. 
When the cells are analyzed by flow cytometry they can be identified as the side 
population (SP), similar to that demonstrated in the hematopoietic system [28-30]. 
Interestingly, SP cells sorted from the mouse breast can regenerate the mammary gland 
after transplantation [29, 31] and have also been identified in the human mammary gland 
[26, 29, 32-34].  An important portion of SP cells loss linage specific markers [26], has 
the capability to generate myoepithelial and luminal cells (Fig. 1) and form branching 
structures in matrigel with both cell lineages [26, 32, 34]. These cells also expressed 
previously identified putative stem cells markers, such as P21 and Mushashi-1, and were 
mainly ER-alpha positive [26].  
The use of putative surface stem cell markers and flow cytometry to identify 
populations with bipotent differentiation capability [26, 35-37] has been also useful in the 
identification of possible stem cells populations. These bipotent progenitors were 
described as ESA (Epithelial Specific Antigen) positive, MUC-1 (mucin-1) positive and 
CALLA negative, and were able to generate ductal-acinar structures [34, 37]. Other 
multiple surface and inner cell markers have been proposed for the identification of 
human stem cells including P21 and Mushashi-1 [26]; Cytokeratins 5/6 and 19 [37, 38]; 
CD49f [36]; EpCAM [37], and Bmi-1 [39]. In the mouse, both Sca-1 and telomerase has 
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been proposed as stem cell makers [24, 29]. More recently, it has been isolated a 
population of cells, defined as Lin-CD29hiCD24+, with self-renewal capacity and the 
ability to regenerate the complete mammary gland [3, 4] (Fig. 1). 
An interesting assay to identify mammary stem cells is based on the parallelistic 
behavior that breast stem cells share with neural stem cells. Undifferentiated multipotent 
progenitors of neural cells can grow in suspension as neurospheres that are rich in stem 
cells [40, 41]. The same conduct has been demonstrated in cells from the mammary gland 
that grow in suspension under serum-free conditions and in the presence of some growth 
factors to form the so-called mammospheres [32, 39, 42]. Interestingly, only SP cells are 
capable to form mammospheres which in turn are enriched in 27% of SP cells [32]. The 
second generation of mammospheres probably lost stem cells properties, since they 
express progenitor markers like CALLA, α6-integrin and only half of the spheres 
contains EpCAM (epithelial cell adhesion molecule) positive cells, a putative stem cell 
marker [37].  
 
Location of Mammary Stem Cells 
An important question to explain is where the stem cells are located within the mammary 
gland. It has been proposed that stem cells are generally positioned in a place called the 
stem cell niche, a specialized spot whose task would be to supply stem cells with the 
proper environment to permit their function correctly [5, 6]. Breast stem cells by 
definition, cannot be committed to any cell lineage, so they should not express any 
differentiation-specific markers. This idea was used in an attempt to localize the 
mammary stem cell niche. In this regard, a population of undifferentiated cells that lack 
the expression of linage-specific markers was located around the terminal end-buds 
(TEB) during the branching ducts, known as cap cells. These cells have been considered 
as candidates for mammary stem cells and are present in both human and mice [43-46]. 
Interestingly, they disappear when the branching process is completed, but the stem cell 
potentiality is not lost and can be manifested again in a next pregnancy. This fact 
suggests other than the cap cells should maintain a dormant stem cell capacity under 
these conditions [8, 47, 48]. Electronic microscope studies in the mouse indicated the 
stem cell function could still be present in the luminal compartment, in the denominated 
 - 7 - 
small light cells [49], that probably are equivalent to the human basal clear cells located 
a the tip of the alveoli by the optic microscope, but it is not clear if these are real stem 
cells, or only myoepithelial cells precursors [50]. In any case, there is increasing evidence 
indicating that mammary stem cells would be located in the luminal compartment; this 
fixes well with the idea that myoepithelial cells are terminal differentiated and very 
difficult to be transformed [51]; but during the physiological remodeling processes, 
mammary stem cell activity can be also localized at the terminal ducts [52]. This stem 
cells would be keratin-5 positive, ESA positive and MUC-1 negative (luminal marker of 
terminally differentiated cells), and they would later acquire markers of terminal 
differentiation, establishing a cell hierarchy in the mammary gland [53] (Fig. 1). 
 
Stem Cell Hierarchy and Cell Fate Decision  
Due to the essential role of estrogen in the mammary gland development and remodeling 
together with its importance in breast cancer growth and treatment, it is of essential 
importance to know how the cell hierarchy in the mammary gland is organized and its 
relationship with estrogens responses. The location of estrogen receptor (ER) positive 
cells in the mammary gland has been a matter of controversy; an interesting scheme of 
stem cell hierarchy regarding the ER receptor has been proposed by Dontu and coauthors 
[54], who propose the existence of most primitive long-term ER negative stem cells 
capable of regenerating a complete mammary gland [2], they would be equivalent to the 
recently identified mammary repopulating units Lin-CD29hiCD24+ and CD49f+ [3, 4] 
(Fig. 1). These cells would lead to the short-term ER positive stem cells capable to 
generate colonies in vitro and patches of mammary epithelium during the adult tissue 
remodeling [20] (Fig. 1). This population would generate the ER negative transit 
amplifying cells that ultimately differentiate to myoepithelial and luminal lineages, 
defined by specific cluster of keratins and markers. Luminal lineage has been defined as 
keratins 7, 8, 18 and 19 positive and ESA+, CALLA +, MUC +; and myoepithelial 
lineage has been identified as keratins 5, 14, 17 positive and smooth muscle actin (SMA) 
positive (Fig. 1). Whereas luminal lineage is determined by the transcription factor 
GATA-3 which in turn induces FOXA1, it is not known what the molecular pathway is 
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which determines myoepithelial cell fate decision. FOXA1 is essential to collaborate with 
ERα in the activation of estrogen pathway-dependable genes [55, 56].  
 
BREAST CANCER STEM CELLS   
There is increasing evidence that stem cells are not only the origin of normal 
tissues, but also the origin of cancer. Tumors would be structured in a cell-hierarchy 
similar to that found in their normal tissue counterparts, resembling, as Pierce suggested, 
caricatures of tissue renewal [9]. Thus cancers would have their own stem cells (cancer 
stem cells), to permit the immortalization of the tumor tissue. The existence of breast 
cancer stem cells was proposed by Pierce and collaborators in the 70’s [10, 11] and a lot 
of pieces of evidence have been built up till then. Epidemiological data from populations 
under radiation exposure suggest that breast cancer develops after decades of the 
oncogenic initiation [12, 13] and stem cells are the only population that live long enough 
to accumulate all the oncogenic alterations needed to generate breast cancer [14-19]. The 
existence of breast cancer stem cells implies both biological and clinical consequences.    
 
Biological Implications 
A complete understanding of the cancer process requires much more detailed knowledge 
of the tumor tissue organization and the origins of neoplastic growth, this means to know 
when the initiated cells begin to show altered behavior. It is therefore necessary to 
identify the initial target cell and its respective contributions to tumor fate determination 
and disruption of local homeostasis. The identification of cancer stem cells has a number 
of biological implications that permits to have a more comprehensive scenario of breast 
cancer.   
 
1. Cell Hierarchy in Breast Cancer  
Tumor tissues have been described by Dvorak as “wounds that do not heal” [57], since 
they no longer respond to normal physiological controls and grow indefinitely. Self-
renewal activity must be present in tumors to permit their progressive growth. However, 
it was not clear if this property was present in all cancer cells or, like normal tissues, 
cancers also have a hierarchical architecture in which only a subpopulation of cells has 
 - 9 - 
self-renewal capacity. Early studies, in both leukemias and solid tumors, demonstrated 
that only a small number of cancer cells have clonogenic potential and are responsible for 
the maintenance of the tumor and the progressive malignant growth [5, 6, 58-62]. This 
was also demonstrated in breast cancer where it was confirmed that not every single cell 
in the tumor has self-renewal properties, instead only a small population of cells was 
capable enough to form tumors when transplanted into immunocompromised NOD-SCID 
mice [63]. These breast cancer stem cells were identified as ESA+, CD44+, CD24low 
and they lack specific lineage markers. Recently, breast cancer propagating cells have 
been isolated and spread in vitro, proliferate extensively in non-adherent mammospheres, 
and interestingly, they still keep some differentiation capacity as they generate both 
myoepithelial and luminal lineages [64]. In summary, the data above indicated the 
existence of a cell hierarchy inside the breast tumors and the existence of breast cancer 
stem cells, but the origin of this cell subpopulation is controversial. 
 
2. Breast Cancer Stem Cell Origin 
The existence of a hierarchy in breast cancer as in the mammary tissue, arise the question 
of cancer-initiating cells. The self-renewal capacity should be originally present in the 
cancer-initiating cells, but it is a question of debate if this is an inner property of the 
initially transformed cell or the oncogenic event activates a stem cell-like program in a 
more differentiated progenitor without self-renewal potential [6]. Although the most 
logical interpretation could be the consideration of normal stem cells as the cancer 
initiating-cells due to its long life and the possibility to accumulate all the necessary 
oncogenic events to be transformed, it has also been indicated that a progenitor cell may 
become a cancer stem cell by acquiring a self-renewal program in different leukemia 
models [65-67] (Fig. 1). In case of breast cancer, mouse models also offer controversial 
results, for example, MMTV-Wnt1 transgenic mice display an expansion of a breast 
cancer stem cell population since they are enriched in CD29hi, CD24+, Sca1+ and 
keratin-6 [3, 23], whereas MMTV-cNeu and H-Ras have a significant reduction in this 
population; for this reason, it has been suggested that the target cells in MMTV-Wnt1 
mice would be a more primitive stem cell than in the other models. In a similar way, in 
human breast cancer, it has been proposed that the existence of two different 
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subpopulations of cancer stem cells; the most primitive one would be the long-term 
repopulating ERα negative stem cell, which might generate ERα negative breast cancer 
stem cells and originate ERα negative tumors; whereas short-term repopulating ERα 
positive stem cells might generate ERα positive breast cancer stem cells that would lead 
to ERα positive tumors [54]. This might indicate that the ERα status of the tumor would 
be determined by the ERα condition of the target cell; but this hypothesis can not explain 
the existence of both kinds of cells in breast tumors. In a broader scenario, this discussion 
raises the question of what determines tumor cell fate.  
 
3. Breast Cancer Cell Fate 
 It is not clear what determines the final breast cancer phenotype; it is possible that this 
might be determined by the grade of differentiation of the target cell where the oncogenic 
event takes place [54]. Another possibility might be that different tumor phenotypes arise 
from the same most primitive target stem cell which could develop partial differentiation 
induced by a particular combination of oncogenic events. The incomplete state of 
differentiation acquired by the cell population generated by those cancer stem cells might 
be reflected in the final tumor phenotype (Fig. 1). An intermediated hypothesis proposes 
the possible existence of a continuum of stem cells with higher to lower possibility to be 
transformed that might explain the existence of different tumor phenotypes [6, 54].  
The best defined phenotypes of breast cancer by expression profiles are the 
luminal and the basal-like tumors. Luminal tumors are mainly ER-positive with or 
without progesterone receptor (PR) and are GATA-3 positive. Basal-like tumors are 
defined by the expression of cytokeratins 5, 14 and 17 and a lack of ER, PR and GATA-3 
expression.  Actually, there is a bunch of mouse models that share features with human 
tumors, including luminal (MMTV-Pymt, MMTV-Neu, Wap-Int, Wap-cMyc) and basal 
(Brca-1 deficient models, Wap-Tag, C3(1)-Tag) [68]; but these promoters tag different 
subpopulations of cells making difficult to elucidate which is the cell of cancer origin. 
The development of new mouse models of breast cancer with the possibility to express 
the oncogenic events in specific cellular subpopulations within the tissue, and the 
expression of specific oncogenic events in the same population, will provide new tools 
for the resolution of these controversial questions.  
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Clinical Implications  
Regardless of whether the target cell for cancer development is a stem cell or one of its 
more differentiated progeny that acquire a stem cell-like program, the final consequence 
will be the same, only a small population of cells with self-renewal capability is essential 
for tumor maintenance [5, 6, 58-63]. The fact that only a small population of tumoral 
cells has self-renewal properties has very important clinical consequences. There is 
increasing evidence that this population is crucial not only for cancer maintenance, but 




 Cancer dissemination is the most dangerous stage in tumor evolution. If only a small 
population of cells is necessary to maintain the primary tumor tissue, the same applies for 
metastatic deposits at distant sites. Although tumors can shed millions of cells into the 
blood, few of them lead to secondary tumors [69], and metastatic growth will therefore 
only be achieved if the cell reaching the site has self-renewal and tumor-maintenance 
capacity. It has been proposed that under physiological conditions adult stem cells could 
move from one tissue to another through the blood vessels and contribute to general 
tissue architecture. Blau and collaborators called this dissemination pathway the “Stem 
Cell Highway” [70]; if this was correct, it seems likely that tumor cell metastasis would 
occur by the same normal process of stem cell spread. In other words, the behavior of 
metastatic cancer cells would mimic the biological properties of normal stem cells (Fig. 
2).  
 
2. Cancer Therapy  
Actual cancer therapies are mainly against proliferative cells, if we assume that cancer 
stem cells could have a similar behavior than their normal counterparts, probably at least 
part of them might be quiescent and refracting to the standard therapies also due to the 
expression of proteins associated with the efflux of drugs that provide resistance to 
multiple chemotherapeutic agents [71-74]. If ERα positive tumors were maintained by a 
small population of ERα negative stem cells, mostly quiescent; this scenario could 
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explain the relapse of these tumors after the treatment with hormonotherapy. To cure 
cancer, we must achieve a complete eradication of the cells with tumor-maintenance 
capacity. If just a single cancer stem cell is spared, the consequence could be recurrence 
within months or even years after the initial treatment. Additionally, cancer stem cells 
would be the tumor subpopulation that acquires the mutations responsible for the 
resistance to standard therapy. Thus one of the main challenges for the next future will be 
the development of new therapeutic strategies for the specific recognition and eradication 
of these cancer stem cells. One possibility would be to introduce therapy strategies that 
induce cancer stem cells differentiation. To understand those pathways implicated in self-
renewal potential, an asymmetric division will be an essential part to develop these new 
strategies of therapy. 
 
3. Tumor Dormancy and Cancer Relapse 
 Cancer recurrence is one of the main problems to solve in clinical practice. Around 50% 
of women with apparent early-stage of breast cancer will develop metastatic disease after 
years of the initial remission. The reactivation of previously dormant cancer stem cells 
[75] could explain the long-term relapse that has been described in leukemias and solid 
tumors such as melanomas and breast cancer [76-80]. The factors that cause dormant 
cancer stem cells to become reactivated are not understood, but might be related to failure 
of the immune system [81] or angiogenesis [82]. Some light might arise from classical 
chemical carcinogenesis studies; two-stage carcinogenesis protocols involve initiation 
with a low dose of a mutagen such as DMBA (7,12-dymethylbenz[a]anthracene) and 
subsequent prolonged exposure to the tumor promoter TPA (12-O-tetradecanoyl 
phorphol-13-acetate). Mice treated with initiating doses of DMBA without subsequent 
promotion by TPA do not develop tumors. However, when promotion with TPA is 
started one year after the exposure to DMBA the tumor response is the same in terms of 
latency and yield, as if it was started one week after initiation. These seminal experiments 
arise important clues: First, these studies implicate a stem cell population as the main 
target for cancer initiation, as only stem cells live long enough to develop tumors after 
long period of time; secondly, exposure of the host to external or internal physiological 
promoter agents can reintroduce initiated long-term dormant cancer stem cells in cycle 
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and originate or reinitiate the tumor. The same might apply for dormant cancer stem cells 
after the first round of treatment with chemotherapy, and the long-term tumor recurrence 
(Fig. 2). It would be important to understand the mechanisms by which stem cells and 
cancer stem cells abandon the cell cycle and are kept in check for such long periods of 
time as well as the process that leads to their reawakening. 
 
 
BREAST CANCER SUSCEPTIBILITY AND STEM CELLS   
 
The classical two-stage chemical carcinogen protocol to induce skin cancer in mice, 
offers an interesting parallelism with breast cancer development. After an application of a 
mutagen like DMBA and subsequent long term promotion with TPA, mice develop skin 
tumors. Indeed, it is well-known that the role of the estrogens as long-term promoter 
agents in breast cancer promotion along the women life; but an issue with essential 
implications is to know the exact moment when the initiation event takes place. Studies 
in populations from Hiroshima and Nagasaki that suffer high dose radiations showed that 
the girls who were between 10 and 14 years of age at the time of radiation exposure were 
the most susceptible population to develop a higher incidence of breast cancer, meaning 
that the puberal breast of young virgin women is very vulnerable to any carcinogenic 
exposure [12]. This behavior has also been demonstrated in mice where viral infection 
with the MMTV (Mouse Mammary Tumor Virus) later than 6 weeks of age after the 
onset of the estrus does not generate mammary tumors [83]. This could indicate that the 
period of maximum susceptibility to breast cancer initiation is early in life. Russo named 
the period of carcinogen susceptibility between the onset of puberty and first pregnancy 
“The Susceptibility Window” [84]. Unfortunately, the initiation agents, apart from 
radiation, in most cases are not known, but epidemiological studies in immigrant 
populations suggest that they seem to be related with multiple factors of the Western way 
of life [85].  
It is well-documented that the protective effect is connected with the early first 
pregnancy in human breast cancer development, the shorter the period till the first 
pregnancy the lower will be the possibility to develop breast cancer [86, 87]. This 
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concept has also been extended to viral and chemical carcinogenesis in mice and rats [84, 
88-95]. Animals were shown to remain susceptible until their first litter and the nursing 
of their pups [84, 97, 98]. This important aspect of breast cancer behavior is not 
recapitulated by most of actual genetic engineering mice (GEM) that use promoters 
induced by estrogens, like the LTR from the MMTV or WAP [68] but, in other contexts, 
it has been also demonstrated that the consequences of aberrant cMYC activation in the 
mammary gland are determined by the developmental state of the gland at the time of 
cMYC exposure [98]. The protection effect of the early pregnancy has been attributed to 
the almost completed differentiation of the mammary gland at the time of the carcinogen 
administration [100]. Mammary carcinomas induced by DMBA to young virgin rats 
come up from the undifferentiated terminal ductal structures identified as TEB [84]. 
During pregnancy and lactation the complete development of the mammary gland is 
manifested by the terminal differentiation of the TEBs into alveolar ducts and lobules. 
This terminal differentiation of the gland would lead to resistance to carcinogens by 
parous mammals. In other words, the incomplete differentiation of the gland at the time 
of carcinogen administration makes it susceptible to develop breast cancer later in life. It 
is demonstrated that there is a change in the breast architecture after the first pregnancy, 
with an increase in cell proliferation and tubular branching. Russo and collaborators 
interpret this transformation as a switch from lobules type 1 and 2 to lobules type 3 and 4,   
where there is a progressive increase in branching and ductal complexity. These authors 
have proposed that breast structures after menopause, in both nulliparous and parous 
women, are again lobules type-1, but those from nulliparous women are susceptible to 
develop cancer. It has been suggested that this fact could be explained by the existence of 
two types of stem cells, type 1 stem cells would be present in type 1 lobules, and after 
pregnancy they would switch to type 2 stem cells which would be refractory to be 
transformed [100-102]. In fact, two possible types of mammary stem cells have also been 
proposed by other group, long-term repopulating ER negative stem cells and short-term 
ER positive stem cells [54] (Fig. 1). It would be very interesting to clarify if there is any 
association between these two concepts. In an attempt to identify the reason of this 
refractivity to cancer development, the gene expression signature of the parous mammary 
gland in rats and mice by expression arrays have been investigated [97, 103, 104]; 
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demonstrating that TGFβ3 levels are upregulated,  among others [97, 103]. It is not well-
understood the process by which an early first pregnancy induces a refractory behavior of 
the mammary gland to cancer development; to know the precise mechanisms by which 
these mechanisms occur would be essential to develop strategies for breast cancer 
prevention.   
 
 
SIGNALING PATHWAYS INVOLVED IN MAMMARY STEM CELL 
RENEWAL   
  
Self-renewal is an essential condition that permits tissues to growth and be maintained in 
physiological conditions, like in tissue repair and remodeling; on the other hand, self-
renewing is a hallmark of cancer. The mechanisms that control cell-renewal in 
physiological and pathological processes seem to be the same, and the deregulation of 
these mechanisms lead to cancer development. Thus cancers could be considered as self-
renewal diseases. There are several signaling pathways that have been related with stem 
cell self-renewal in the mammary gland and have been implicated simultaneously in 
embryonic breast development, adult tissue remodeling, and breast cancer generation. 
 
Wnt Pathway 
 There is a number of data involving Wnt pathway with mammary stem cell self-renewal. 
Firstly, Wnt signaling has been implicated in mammary gland morphogenesis and 
development; in both early stages of the mammary gland embryogenesis and adult tissue 
remodeling during pregnancy and lactation. Several Wnt ligands are expressed 
differentially at different stages of the mammary gland development [105, 106], and 
deregulation of the pathway leads to gland structural defects, for example, Wnt-4 
deficiency leads to a delay in side-branching [107]. Secondly, Wnt signaling pathway is 
active in more than 50% of carcinomas [108]. The participation of Wnt pathway in breast 
cancer development seems to be complex, since some members of the pathway, for 
example Wnt-7, seem to be downregulated [109], whereas others, like Wnt-2, are 
overexpressed in breast cancer [110]. This ambivalent function also could have clinical 
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implications since it has been described a possible suppressor effect in some components 
of the pathway; this would be the case of Wnt-5a whose loss leads to an increasing risk of 
relapse in ductal breast cancer whereas its presence has been indicated as a sign of good 
prognosis [111].  
The deregulation of Wnt pathway not only delay the self-renewal program but 
also seems to block the differentiation process altering the gland morphogenesis; for 
example, the overexpression Wnt-1 or Wnt-10b in transgenic mice generate premature 
ductal branching and alveolar development leading to lobule-alveolar hyperplasias that 
eventually progress to breast cancer [105, 106]. A similar phenotype has been reproduced 
with the overexpression of the downstream component β-Catenin in transgenic mice 
[105, 106]. Moreover, mice that overexpress Wnt-1 or an active form of β−catenin 
present an expansion of undifferentiated precursors in the SP [22], and the size of this SP 
correlate with the risk of tumor development [112] indicating a direct implication of Wnt 
pathway in mammary stem cell self-renewal.  
 
Notch Pathway 
 Notch pathway has been also related with mammary stem cell self-renewal. In particular, 
some members of Notch pathway, like Notch-4, seem to participate in normal mammary 
gland development, and the overexpression of Notch-4 in vitro promotes branching 
morphogenesis and blocks the differentiation of normal breast epithelial cells [113]. 
Moreover, transgenic mice that overexpress Notch-4 also develop dysplasias and breast 
tumors [114-116]. Notch family has also been implicated in breast cancer, for example, 
Notch-4 is up-regulated in different human breast cancer cell lines [117] and Notch-1 can 
transform normal breast epithelial cells of some mice like HC11 [118]. But the role of 
Notch family in breast cancer seems to be dual; the overexpression of Notch-1 in tumors 
has been related with poor prognosis, and Notch-2 overexpression has been related with 
good prognosis [119]. The use of in vitro assays is helping to dissect the complex role of 
Notch pathway in breast physiology and pathology. The stimulation or inhibition of this 
pathway, in particular Notch-4, in non-adherent in vitro mammospheres demonstrated 
that this pathway not only promotes self-renewal in stem cells, but also the proliferation 
in early progenitors. Interestingly, this pathway also exerts its action in cell fate 
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determination, facilitating the commitment to the myoepithelial lineage and preventing 
terminal differentiation [42].  
  
Hedgehog Pathway 
 Hedgehog signaling has been also implicated in the maintenance of both stem and 
progenitor cells of the mammary gland. There are indirect evidences that suggest the 
implication of Hedgehog signaling in stem cell self-renewal of the mammary tissue. 
Firstly, Hedgehog pathway has been implicated in breast embryonic development and 
adult tissue remodeling, and the disruption of Ptc-1 receptor or Gli-2 transcription factor 
generate ductal dysplasias in transgenic mice [120, 121]. Secondly, Hedgehog signaling 
has also been related with breast cancer development; for example, it has been described 
that the importance of certain polymorphisms of Ptc-1 in the risk of breast cancer is 
associated with the use of oral contraceptive hormones [122], and the existence of Ptc1 
mutations in breast cancer [123]. On the other hand, cyclopamine, a potent hedgehog 
pathway inhibitor, inhibit the growth of breast cancer cell lines in vitro.     
Others pathways that have been implicated in mammary stem cell self-renewal 
are: ERα [54]; TGFβ [124, 125], LIF [126], Prl/GH [32] and EGF [32]. It is not well-
understood how these pathways interact in a global scenario to regulate self-renewal 
capability in stem cells. It is interesting to note that deregulation of Wnt, Notch or 
Hedgehog signaling pathways originate alterations in self-renewal activity and, at the 
same time, in the differentiation program. In many cases the block in the differentiation 
precludes cancer development, an association that has also been well-established in 
hematopoietic malignancies. This similitude could indicate a common mechanism for 
cancer development in tumors from both epithelial and mesenchymal origin.  
 
 
FUTURE PERSPECTIVES   
 
The existence of cancer stem cells has important consequences in the breast cancer field 
and, in particular, in cancer prevention and therapy. Since it seems that the oncogenic 
events that initiate breast cancer occurs in stem cells early in life [12], it would be very 
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important to identify those agents responsible for breast cancer initiation. In this sense, 
epidemiological studies comparing breast cancer development in countries with low and 
high incidence of the disease, and migratory movements offer a unique scenario to study 
the environmental effect on breast cancer development and would be essential in breast 
cancer prevention [127]. 
Another important issue would be to entirely understand the process that leads to 
the protective effect of pregnancy in breast cancer development. There are still a number 
of questions to be answered; for example it is not clear why the first pregnancy exerts the 
protective effect only early in life or, in other words, why a pregnancy later in life is not 
so efficient to eliminate those putative stem cells susceptible to be initiated.  In any case, 
this interesting hypothesis offers a rationale for breast cancer prevention. Exciting studies 
have been carried out already in rodents [88-99] but it is controversial if this approach 
could have any benefit in women with high susceptibility to breast cancer, like in Brca1-
deficient patients [128]; indeed, the same lack of protection has been demonstrated in P53 
deficient mice [129]. In any case, it could be possible that most women with sporadic 
forms of breast cancer could be benefited from similar strategies of prevention. 
The possibility that cancers arise and are maintained from a small population with 
stem cell capacity indicates that components of the self-renewal and asymmetric division 
pathways could be the targets for more effective therapies. One possibility for cancer 
therapy would be to develop methods to encourage stem cells to disrupt their asymmetric 
division and leave their undifferentiated self-renewing state entering in tissue specific 
differentiation programmes. Several examples already exist in which differentiation 
inducing agents, such us retinoid acid or PPAR-γ agonists, have been used for the 
treatment of M3 acute myeloid leukemia and myxoid liposarcoma, respectively [130, 
131]. Although normal stem cells function probably relies on very similar if not the same 
molecular mechanisms, it will be a challenge to develop therapies that discriminate 
between normal and cancer stem cells, but there is no doubt that switching off the stem 
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Figure legends 
 
Fig. (1). Mammary stem cell hierarchy and breast cancer phenotype. (A) Simplified 
model of epithelial cell hierarchy in the mammary gland: LTSC-MRU (Long-Term Stem 
Cell Mammary Regenerating Unit), STSC-MRU (Short-Term Stem Cell Mammary 
Regenerating Unit). (B and C) Proposed models to explain breast cancer ontology: (B) 
The final phenotype of each breast cancer subtype would reflect the phenotype of the 
lineage of the initiating cell. (C) In the second model, all breast tumor subtypes would 
have the origin in the same primitive pool of mammary stem cells, which would initiate a 
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Fig. (2). Clinical implications of breast cancer stem cell hypothesis. (A) Stem cells (SC) 
are the only subpopulation with self-renewal capability and are responsible for tissue 
maintenance, most part of them are quiescent in G0. (B) After an oncogenic mutation SC 
can be initiated, these initiated cells also can be dormant in G0 for long periods of time. 
(C) After promotion stimuli these initiated cells divide and acquire secondary mutations 
and eventually are transformed in cancer stem cells (CSCs), which, as their normal 
counterparts, can be in G0 for a long period of time. (D) CSCs generate and maintain the 
tumor tissue, and (E) can metastasize and originate long distant tumors. (F) After the 
treatment with standard therapies, most part of tumoral cells are eliminated, (G) but 
cancer stem cells, that are mostly quiescent in G0, are resistant to quimiotherapy and lead 
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